Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Allogeneic genetically engineered human umbilical vein endothelial cells”In the company’s words, NCT05181540 on ClinicalTrials.gov
- Tested for
- Hodgkin Lymphoma (2 trials), Non Hodgkin Lymphoma, Non-hodgkin Lymphoma
- Main trialPhase 3
- “High-dose chemotherapy followed by blood stem cell transplantation is administered to lymphoma patients with an intention to cure. However, high-dose chemotherapy simultaneously causes damage to healthy tissues that frequently result in severe complications that lead to hospitalization and can be life threatening. These severe complications involve the blood, immune, gastro-intestinal systems, and other vital organs. The purpose of this study is to determine if experimental therapy AB-205 (study drug) can prevent or reduce the occurrence and duration of the severe chemotherapy related…”In the company’s words, NCT05181540 on ClinicalTrials.gov
- Other names
- E-CEL cells
Other drugs for Hodgkin Lymphoma
- PembrolizumabMerck & Co. · Phase 2
- VI-0609VIVUS LLC · Phase 2
- AZD3470AstraZeneca · Phase 1/2
- CD30.CAR-TTessa Therapeutics · Phase 2
- CobolimabGSK · Phase 1/2
- DostarlimabGSK · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Terminated | 29 Dec 2023 | A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation | |
| Phase 1Completed | 18 Nov 2020 | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026